BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26997452)

  • 1. p16 expression predicts neoadjuvant tumor necrosis in osteosarcomas: reappraisal with a larger series using whole sections.
    Kosemehmetoglu K; Ardic F; Karslioglu Y; Kandemir O; Ozcan A
    Hum Pathol; 2016 Apr; 50():170-5. PubMed ID: 26997452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
    Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
    Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
    Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
    Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
    Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
    Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitronectin significantly influences prognosis in osteosarcoma.
    Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
    Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.
    Tang Y; Yang C; Guo Z; Fu Y; Yu X; Liu B; Zhou H; Wang J; Li W; Pang Q
    Medicine (Baltimore); 2017 May; 96(19):e6714. PubMed ID: 28489748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
    Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
    Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
    Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.
    Le Guellec S; Moyal EC; Filleron T; Delisle MB; Chevreau C; Rubie H; Castex MP; de Gauzy JS; Bonnevialle P; Gomez-Brouchet A
    Hum Pathol; 2013 Oct; 44(10):2149-58. PubMed ID: 23845472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy-induced changes in osteosarcoma after neoadjuvant chemotherapy (COSS 86 Therapy Study). Correlation between morphologic findings and clinical follow-up].
    Werner M; Fuchs N; Salzer-Kuntschik M; Winkler K; Delling G
    Pathologe; 1996 Jan; 17(1):35-43. PubMed ID: 8685094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.
    Masrouha KZ; Khattab R; Tawil A; Abdallah A; Saghieh S; Haidar R; Abboud M; Khoury NJ
    J Bone Joint Surg Br; 2012 Mar; 94(3):419-24. PubMed ID: 22371553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy.
    Wang J; Sun M; Liu D; Hu X; Pui MH; Meng Q; Gao Z
    Acta Radiol; 2017 Aug; 58(8):971-976. PubMed ID: 27852643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma.
    Cates JMM
    Am J Surg Pathol; 2018 Apr; 42(4):485-491. PubMed ID: 29200101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of thallium-201 scintigraphy in assessment of neoadjuvant chemotherapy for osteosarcoma].
    Huang ZK; Lou C; Fang XQ
    Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):769-72. PubMed ID: 20021831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
    Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jung ST; Jeon DG
    J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy.
    Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
    Hum Pathol; 1998 Oct; 29(10):1050-5. PubMed ID: 9781640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
    Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
    Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
    Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.